Advanced Search

Technical Analysis for SURF - Surface Oncology, Inc.

Grade Last Price % Change Price Change
F 9.02 6.37% 0.54
SURF closed up 6.37 percent on Monday, March 1, 2021, on 57 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical SURF trend table...
Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 6.37%
Lower Bollinger Band Walk Weakness 6.37%
Wide Bands Range Expansion 6.37%
Oversold Stochastic Weakness 6.37%
180 Bearish Setup Bearish Swing Setup 6.87%
Lower Bollinger Band Walk Weakness 6.87%
Wide Bands Range Expansion 6.87%
Lower Bollinger Band Touch Weakness 6.87%
Older End-of-Day Signals for SURF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 6 hours ago
Rose Above Previous Day's High about 11 hours ago
Up 5% about 11 hours ago
Up 3% about 11 hours ago
Up 2% about 11 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators Basic chart:

Profile

Surface Oncology is a clinical-stage immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47 and CD73. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response, alone or in combination with other therapies. The company has a pipeline of immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Immunotherapy Cancer Treatments Cancer Immunotherapy Virotherapy Tumor Immunotherapies Cancer Research Novel Cancer Cd73 CD47 Active Immunotherapy Tumor Microenvironment

Is SURF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Feb 24 Surface Oncology to Participate in Upcoming March Investor Conferences
Feb 23 The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Feb 22 Going Under The Covers With Surface Oncology
Feb 22 What Type Of Shareholders Make Up Surface Oncology, Inc.'s (NASDAQ:SURF) Share Registry?
Feb 11 Surface Oncology promotes chief medical officer as new CEO
Feb 11 Surface Oncology to Appoint Robert Ross, M.D., as President and Chief Executive Officer
Jan 21 The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Jan 19 Surface Oncology Is Set for Further Gains - How to Buy It
Jan 17 Cramer Shares His Thoughts On American Airlines, American Tower And More
Jan 15 The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
See more SURF news...

Indicators

Indicator Value
52 Week High 14.38
52 Week Low 1.38
Average Volume 1,603,268
200-Day Moving Average 7.61
50-Day Moving Average 10.57
20-Day Moving Average 10.35
10-Day Moving Average 9.34
Average True Range 0.85
ADX 26.09
+DI 15.73
-DI 31.19
Chandelier Exit (Long, 3 ATRs ) 10.15
Chandelier Exit (Short, 3 ATRs ) 10.56
Upper Bollinger Band 12.79
Lower Bollinger Band 7.92
Percent B (%b) 0.23
BandWidth 46.98
MACD Line -0.63
MACD Signal Line -0.37
MACD Histogram -0.2613
Fundamentals Value
Market Cap 366.9 Million
Num Shares 40.7 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -6.80
Price-to-Sales 6.80
Price-to-Book 3.88
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.83
Resistance 3 (R3) 9.78 9.46 9.70
Resistance 2 (R2) 9.46 9.25 9.49 9.65
Resistance 1 (R1) 9.24 9.13 9.35 9.29 9.60
Pivot Point 8.92 8.92 8.98 8.95 8.92
Support 1 (S1) 8.70 8.71 8.81 8.75 8.44
Support 2 (S2) 8.38 8.59 8.41 8.39
Support 3 (S3) 8.16 8.38 8.35
Support 4 (S4) 8.21